The National Eye Institute is offering this grant, the NEI Translational Research Program for Therapeutics (R33), to accelerate the translation of innovative laboratory research into therapies for visual system diseases. This grant supports multidisciplinary teams in generating preclinical data for developing biological, pharmacological, medical device, or combination product interventions. The ultimate goal is to provide new technological, biological, and pharmacological resources to clinicians and their patients. Projects must define clear milestones supporting the development of a therapeutic or device, leading to an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application with the FDA. This specific R33 focuses on advancing a single therapeutic candidate through IND/IDE-enabling studies and designing future clinical trials.
Opportunity ID: 348936
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-23-205 |
| Funding Opportunity Title: | NEI Translational Research Program for Therapeutics (R33 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.867 — Vision Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Jun 27, 2023 |
| Last Updated Date: | Jan 07, 2025 |
| Original Closing Date for Applications: | Mar 16, 2025 |
| Current Closing Date for Applications: | Jan 06, 2025 |
| Archive Date: | Feb 05, 2025 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $1,000,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Special district governments Public and State controlled institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts State governments Private institutions of higher education City or township governments Others (see text field entitled “Additional Information on Eligibility” for clarification) County governments Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Public housing authorities/Indian housing authorities |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: |
The purpose of this NOFO is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. Multidisciplinary teams of scientists and clinicians must focus on generating preclinical data that will lead to the development of biological, pharmacological, medical device and/or combination product interventions. The ultimate goal of this program is to make new technological, biological and pharmacological resources available to clinicians and their patients.The steps towards this goal should be clearly delineated in a series of milestones that support the development of a therapeutic or device that will lead to an Investigational New Drug (IND) or Investigational Device Exception (IDE) application to the U.S. Food and Drug Administration (FDA) and/or testing in a clinical trial.The R33 is to focus on advancing a single therapeutic candidate through IND/IDE -enabling studies, filing an IND package with the FDA, and designing future clinical trials. Applicants pursuing early stage applied research should consider the companion (R61/R33) NOFO PA-23-XXX. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/pa-files/PAR-23-205.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| Modification to close date | Jan 07, 2025 | |
| Jun 27, 2023 |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-23-205 |
| Funding Opportunity Title: | NEI Translational Research Program for Therapeutics (R33 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.867 — Vision Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Jun 27, 2023 |
| Last Updated Date: | Jan 07, 2025 |
| Original Closing Date for Applications: | Mar 16, 2025 |
| Current Closing Date for Applications: | Jan 06, 2025 |
| Archive Date: | Feb 05, 2025 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $1,000,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Special district governments Public and State controlled institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts State governments Private institutions of higher education City or township governments Others (see text field entitled “Additional Information on Eligibility” for clarification) County governments Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Public housing authorities/Indian housing authorities |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: |
The purpose of this NOFO is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. Multidisciplinary teams of scientists and clinicians must focus on generating preclinical data that will lead to the development of biological, pharmacological, medical device and/or combination product interventions. The ultimate goal of this program is to make new technological, biological and pharmacological resources available to clinicians and their patients.The steps towards this goal should be clearly delineated in a series of milestones that support the development of a therapeutic or device that will lead to an Investigational New Drug (IND) or Investigational Device Exception (IDE) application to the U.S. Food and Drug Administration (FDA) and/or testing in a clinical trial.The R33 is to focus on advancing a single therapeutic candidate through IND/IDE -enabling studies, filing an IND package with the FDA, and designing future clinical trials. Applicants pursuing early stage applied research should consider the companion (R61/R33) NOFO PA-23-XXX. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/pa-files/PAR-23-205.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-23-205 |
| Funding Opportunity Title: | NEI Translational Research Program for Therapeutics (R33 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.867 — Vision Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jun 27, 2023 |
| Last Updated Date: | Jun 27, 2023 |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Mar 16, 2025 |
| Archive Date: | Apr 21, 2025 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $1,000,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Public and State controlled institutions of higher education State governments Independent school districts City or township governments Others (see text field entitled “Additional Information on Eligibility” for clarification) Native American tribal governments (Federally recognized) County governments Public housing authorities/Indian housing authorities Private institutions of higher education For profit organizations other than small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this NOFO is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. Multidisciplinary teams of scientists and clinicians must focus on generating preclinical data that will lead to the development of biological, pharmacological, medical device and/or combination product interventions. The ultimate goal of this program is to make new technological, biological and pharmacological resources available to clinicians and their patients. The steps towards this goal should be clearly delineated in a series of milestones that support the development of a therapeutic or device that will lead to an Investigational New Drug (IND) or Investigational Device Exception (IDE) application to the U.S. Food and Drug Administration (FDA) and/or testing in a clinical trial. The R33 is to focus on advancing a single therapeutic candidate through IND/IDE -enabling studies, filing an IND package with the FDA, and designing future clinical trials. Applicants pursuing early stage applied research should consider the companion (R61/R33) NOFO PA-23-XXX. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/pa-files/PAR-23-205.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Related Documents
Folder 348936 Full Announcement-PAR-23-205 -> PAR-23-205-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-H | Use for due dates on or before January 24, 2025 | PKG00282317 | Jul 24, 2023 | Jan 08, 2025 | View | |
| FORMS-I | Use for due dates on or after January 25, 2025 | PKG00289013 | Nov 25, 2024 | Jan 08, 2025 | View |
Package 1
Mandatory forms
348936 RR_SF424_5_0-5.0.pdf
348936 PHS398_CoverPageSupplement_5_0-5.0.pdf
348936 RR_OtherProjectInfo_1_4-1.4.pdf
348936 PerformanceSite_4_0-4.0.pdf
348936 RR_KeyPersonExpanded_4_0-4.0.pdf
348936 RR_Budget_3_0-3.0.pdf
348936 PHS398_ResearchPlan_5_0-5.0.pdf
348936 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
348936 RR_SubawardBudget30_3_0-3.0.pdf
348936 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
348936 RR_SF424_5_0-5.0.pdf
348936 PHS398_CoverPageSupplement_5_0-5.0.pdf
348936 RR_OtherProjectInfo_1_4-1.4.pdf
348936 PerformanceSite_4_0-4.0.pdf
348936 RR_KeyPersonExpanded_4_0-4.0.pdf
348936 RR_Budget_3_0-3.0.pdf
348936 PHS398_ResearchPlan_5_0-5.0.pdf
348936 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
348936 RR_SubawardBudget30_3_0-3.0.pdf
348936 PHS_AssignmentRequestForm_4_0-4.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
